Tetra Bio-Pharma Goes After the Cannabis Oil Medical Market and Launches a Phase 4 Trial with Cannabis Oils in …

OTTAWA, ONTARIO–(Marketwired – Oct. 26, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the launch of a medical cannabis oil program as it targets penetrating the lucrative cannabis oil market and strengthens its plans to generate revenues from the medical cannabis market.

Last year Tetra launched several drug development programs to commercialize cannabis-based prescription drugs making it one of the world leaders in cannabinoid pharmaceuticals. Tetra’s vision is to develop an evidence-based approach similar to that of any other prescription drug, thereby allowing physicians and pharmacists to prescribe and dispense these medicines to patients in need. Despite the growing popularity of cannabis oils, physicians and pharmacists across Canada are hesitant to support the use of these products because of the lack of data supporting its medical use; even though healthcare professionals have to offer the best available

... read more at: http://www.marketwired.com/press-release/-2238499.htm